Bupropion and Sexual Dysfunction: Evidence‑Based Guidance

Guideline Recommendations

• The American College of Physicians states that bupropion produces a significantly lower rate of sexual adverse events than fluoxetine or sertraline in head‑to‑head trials, supporting its use as the preferred first‑line antidepressant when sexual side effects are a concern. Strength of evidence: highest‑quality (multiple randomized trials). 1

Comparative Sexual Side‑Effect Rates

• Across large meta‑analyses, bupropion is associated with markedly lower rates of sexual dysfunction compared with other antidepressants, and it is recommended as the preferred first‑line agent when patients are worried about sexual side effects. Strength of evidence: high (systematic review of randomized controlled trials). 2

Depression‑Related Sexual Dysfunction

• In patients with depression, sexual dysfunction occurs in approximately 40–45 % of women and 20–30 % of men, independent of medication effects. This underscores the importance of treating the underlying mood disorder to improve sexual health. Strength of evidence: moderate (observational data from endocrine practice studies). 3

Limitations of Trial Reporting

• Absolute rates of sexual dysfunction are likely under‑reported in clinical trials of antidepressants because assessment methods vary widely and few studies employ standardized objective scales. Strength of evidence: moderate (methodological review). 1

Safety Considerations

• Bupropion is contraindicated in patients at risk for seizures (e.g., history of stroke, brain metastases) because it carries a modest increased seizure incidence of about 1 per 1,000 patients, especially among those with predisposing factors. Strength of evidence: moderate (prospective safety data). 4

Bupropion as First‑Line Alternative to Reduce Antidepressant‑Induced Sexual Dysfunction

Evidence and Guideline Recommendations

• The American College of Physicians recommends bupropion as the preferred antidepressant when sexual dysfunction is a concern, because it is associated with lower rates of sexual adverse events than fluoxetine or sertraline. 5
• Switching from a serotonergic antidepressant (e.g., sertraline) to bupropion is advised for adult patients experiencing medication‑related sexual side effects, as bupropine shows the lowest incidence of sexual dysfunction among commonly prescribed antidepressants while providing comparable efficacy for anxiety, depression, and irritability. 5
• Paroxetine has the highest reported rates of sexual dysfunction among SSRIs; therefore, substituting sertraline with paroxetine would likely worsen sexual side effects. 5

Pharmacologic Mechanism

• Bupropion’s action as a dopamine‑ and norepinephrine‑reuptake inhibitor without serotonergic activity underlies its favorable sexual‑side‑effect profile, distinguishing it from SSRIs that commonly impair sexual function. 6

Combination Therapy

• Adding bupropion to an ongoing sertraline regimen can mitigate sertraline‑induced sexual dysfunction and restore sexual function while preserving overall antidepressant efficacy. 6

Clinical Implementation

• The American College of Physicians advises clinicians to assess treatment response within 1–2 weeks after switching to bupropion, enabling early detection of benefits or adverse effects. 5

All statements are supported by the cited references and reflect guideline‑based recommendations for managing antidepressant‑related sexual dysfunction.